Calcium regulating drugs
Drug Safety Update
December 2014: Calcitonin (Miacalcic): increased risk of cancer with long-term use. See also see BNF for safety guidance.
National Guidance
See drug specific NICE Guidance links below
National Osteoporosis Guideline Group (NOGG) Clinical guideline for the prevention and treatment of osteoporosis
TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in post menopausal women, updated February 2018
Calcitonin is a hormone produced by the thyroid gland and is involved in helping to regulate levels of calcium and phosphate in the blood, opposing the action of parathyroid hormone and slows bone turnover. Calcitonin is licensed for prevention of bone loss due to sudden immobility, hypercalcaemia of malignancy and for the treatment of Paget's disease. It is not recommended for osteoporosis treatment because benefit is outweighed by the risk of malignancy associated with long-term use.
Teriparatide is a recombinant protein form of parathyroid hormone. It is licensed for the treatment of osteoporosis in post menopausal women and in men at increased risk of fractures. Use can only be initiated by a specialist consultant according to NICE guidance.
| Pack |
|---|
| 5 ampoule |
| Pack |
|---|
| 5 ampoule |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 pre-filled disposable injection (28 doses) |
| Pack |
|---|
| 1 pre-filled disposable injection |
| 3 pre-filled disposable injection |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary